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Differential association of 
ezetimibe-simvastatin combination 
with major adverse cardiovascular 
events in patients with or without 
diabetes: a retrospective propensity 
score-matched cohort study
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Bong-Soo Cha1,2 & Eun Seok Kang  1,2
Clinical trials suggested that the benefits of ezetimibe-statin combination therapy on major adverse 
cardiovascular events (MACE) might be greater in patients with diabetes. We aimed to investigate the 
differential association of ezetimibe-statin combination with incident MACE by presence of diabetes. 
In this retrospective cohort study, subjects treated with simvastatin 20 mg plus ezetimibe 10 mg (S + E) 
or simvastatin 20 mg alone (S) between 2005 and 2015 were 1:1 matched using propensity score as 
stratified by diabetes. Primary outcome was newly-developed MACE composed of cardiovascular 
death, ACS, coronary revascularization, or non-hemorrhagic stroke. During 5,077 and 12,439 person-
years, the incidence rates of MACE were 24.9, 20.1, 35.3, and 22.8/1000 person-years among no 
diabetes S, no diabetes S + E, diabetes S, and diabetes S + E, respectively. Relative to no diabetes S, 
adjusted HR (aHR) for MACE in diabetes S was 1.23 (p = 0.086), whereas S + E was associated with 
a lower risk of MACE in both non-diabetic patients (aHR 0.76, p = 0.047) and diabetic patients (aHR 
0.60, p = 0.007) with significant difference (relative excess risk due to interaction = −0.39, p = 0.044). 
In conclusion, reduction of MACE risk associated with ezetimibe plus simvastatin therapy relative to 
simvastatin alone was greater in patients with diabetes than in patients without diabetes.
Atherosclerotic cardiovascular (ASCVD) disease remains the main cause of mortality and morbidity in patients 
with diabetes1,2. Despite the substantial decline in the incidence rate of diabetes-related cardiovascular compli-
cations in the past two decades, patients with diabetes still continue to have higher risk of vascular complications 
compared to individuals without diabetes3. Analyses of nationally representative data of the United States showed 
that patients with diabetes had 1.8- and 1.5-fold higher age-standardized rates of acute myocardial infarction 
(45.5 vs. 25.8 cases/10000 persons) and stroke (52.9 vs. 34.3 cases/10000 persons), respectively3. These findings 
suggest that there are still unmet needs for optimizing pharmacologic strategies to reduce cardiovascular risk in 
patients with diabetes.
A large randomized trial (IMPROVE-IT) including 18144 patients with recent acute coronary syndrome 
(ACS) showed that 10 mg ezetimibe plus 40 mg simvastatin therapy reduced the risk of major adverse cardiovas-
cular events (MACE) compared to simvastatin alone4. A subsequent study from the IMPROVE-IT trial reported 
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that a greater reduction of MACE risk was observed in patients with diabetes on ezetimibe plus simvastatin than 
in patients without diabetes5. These findings support the recommendations from recent guidelines on manage-
ment of dyslipidemia that ezetimibe can be a useful non-statin therapy in high-risk patients with diabetes and 
established ASCVD6–9. However, studies focused on the differential effect of ezetimibe-statin combination ther-
apy versus statin alone on CV outcomes among patients with or without diabetes in real-world settings are scarce 
yet.
In this study, we conducted a retrospective observational cohort study with propensity score matching to 
compare the association of ezetimibe plus simvastatin therapy versus simvastatin alone with the risk of MACE in 
individuals with or without diabetes.
Materials and Methods
Study design and population. We conducted a propensity score-matched, observational, retrospective 
cohort study using longitudinal data retrieved from the electronic registry of the tertiary-level, university-af-
filiated Severance Hospital, Yonsei University College of Medicine. This study was approved by Institutional 
Review Board of Severance Hospital, Yonsei University (no. 4-2015-0637). All methods were performed in 
accordance with the relevant guidelines and regulations. Requirement to obtain informed consent was waived 
by the Institutional Review Board for this study based on the retrospective chart review design only with no 
more than minimal risk. Patients aged 19 years or older those who received prescriptions for simvastatin 20 mg 
plus ezetimibe 10 mg (S + E) or simvastatin 20 mg alone (S) for at least 180 days or more between January, 2005, 
and June, 2015 were identified to establish the study cohort. We compared the incidence of CV outcomes in 1:1 
matched cohorts using propensity score (S + E vs. S) within the strata of diabetes and no diabetes and we tested 
the presence of significant interaction between diabetes and ezetimibe-simvastatin combination. Baseline data 
within 6 months before drug prescription were extracted regarding demographics, comorbidities, body mass 
index (BMI), smoking status, alcohol drinking status, medications, and laboratory measurements including 
serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-C, fasting glucose, and creati-
nine levels. Individuals with the presence of any International Classification of Diseases 10th revision (ICD-10) 
diagnosis codes of diabetes (E10.0–E14.9) plus evidence of continuous prescription of any type of anti-diabetes 
medications for ≥60 days were defined as having diabetes. The index date was the first day of S + E or S prescrip-
tion. Comorbidities were identified by ICD-10 codes as follows: hypertension, I10.0, I10.1, I10.9; unstable angina, 
I20; myocardial infarction, I21.0-I24.9, I25.2; non-haemorrhagic stroke, I64, G46.3, G46.4, I63.9, I69.319; chronic 
kidney disease, N18.2, N18.3, N18.4, N18.5, N18.9. Medications at baseline were identified from the hospital 
prescription records using the national insurance drug codes. Blood samples after overnight fast were assessed 
using an auto-analyzer (Hitachi 7600-110 automated chemistry analyzer, Hitachi Company, Tokyo, Japan) at the 
central laboratory of the Severance Hospital. Individuals with end-stage renal disease on renal replacement ther-
apy, malignancy, or liver cirrhosis before the index date were excluded from the analysis (Fig. 1).
Outcomes. The primary composite outcome was MACE composed of CV death, ACS (non-fatal myocar-
dial infarction or unstable angina requiring hospitalization), coronary revascularization (percutaneous coronary 
intervention or coronary artery bypass graft), and non-fatal, non-hemorrhagic stroke. The occurrence of MACE 
was identified by ICD-10 codes entered at the time of hospital admission or at emergency department during 
follow-up periods with ascertainment by diagnosis codes entered at the time of hospital discharge. Consistency of 
CV outcomes was adjudicated by reviewing the individual medical records. The causes of death were confirmed 
based on death certificates and/or primary discharge diagnosis codes at last admission. Data of subjects were 
followed until incident MACE, lost to follow-up, death, or 31 December 2015.
Statistical analysis. Logistic regression models were established to estimate the propensity score for 
being allocated to S + E or S in each stratum of diabetes and no diabetes. For the estimation of propensity score, 
Figure 1. Propensity score-matched cohort study flow chart. S + E indicates individuals treated with simvastatin 
20 mg plus ezetimibe 10 mg whereas S indicates those treated with simvastatin 20 mg alone. Of 8,136 subjects, 
5,829 subjects without excluding criteria were first stratified by presence of diabetes. Matched S + E and S in the 
strata of diabetes and no diabetes remained in final analysis.
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clinical characteristics (sex, age, BMI, current smoking, history of hypertension, unstable angina, non-fatal 
myocardial infarction, ischemic stroke, chronic kidney disease, current use of aspirin, clopidogrel, beta-blocker, 
renin-angiotensin system blockers, serum glucose, total cholesterol, LDL-C, HDL-C, triglyceride, creatinine lev-
els, current use of metformin, sulfonylurea, insulin, and other diabetes medications) were included as model 
predictors. A nearest-neighbor algorithm on a 1:1 basis without replacement within a caliper of 0.01 was used 
to match patients. We checked covariate balance using standardized difference of mean between groups with a 
threshold of 10% to determine substantial imbalance (Supplemental Figs 1 and 2). The time to occurrence of 
MACE between matched groups was compared by plotting Kaplan-Meier curves with a log-rank test. To compare 
the influence of diabetes on the association between the ezetimibe-statin combination therapy and MACE, we 
calculated hazard ratio [HR] and adjusted HR of MACE associated with the use of S + E (vs. S) as stratified by dia-
betes. To test whether there is a significant interaction between the effect of ezetimibe-simvastatin combination 
therapy on MACE and presence of diabetes, we first calculated the relative excess risk due to interaction (RERI) 
as a formal test of additive interaction, which is known as the best measurement for interaction in Cox model10. 
RERI is determined as HR11 − HR10 − HR01 + HR00 in which HR00 denotes S users without diabetes (reference 
population). HR10 and HR01 represent S + E users without diabetes or S users with diabetes. HR11 denotes the 
HR of individuals with diabetes those who received S + E treatment. RERI = 0 means no interaction, whereas 
RERI > 0 or RERI < 0 means presence of significant positive or negative interaction. To test the presence of inter-
action in multiplicative scale, we next included a product term of presence of diabetes and treatment groups 
(S + E vs. S) in the multivariate Cox model and tested the statistical significance of coefficient of the product term. 
A two-sided p value of <0.05 was considered as significant. All statistical analyses were performed with STATA 
12.0 (Stata Corp., TX, USA).
Data availability. The datasets used and/or analyzed during this study are available from the corresponding 
author on reasonable request.
Results
Baseline characteristics. Among 8136 eligible subjects, we included 5829 subjects for propensity score 
matching after exclusion of individuals with any documented history of end-stage kidney or liver diseases and 
malignancy before index date. After propensity score matching, a total of 3674 subjects (S + E 545 vs. S 545 
in diabetes group; S + E 1292 vs. S 1292 in no diabetes group) remained in the end for this analysis (Fig. 1). 
Approximately 50% of the subjects were men with a mean age of 68 years (Table 1). Most patients (81.4%) did 
not have any history of MACE. Baseline variables did not differ significantly among matched S + E and S groups 
within the strata of diabetes and no diabetes. Compared with patients without diabetes, patients with diabetes 
had higher prevalence of older age, male sex, previous unstable angina, non-fatal MI, more CV medications use, 
higher triglyceride levels, and lower HDL-C and LDL-C levels.
Outcomes. During follow-up periods of 5,077 and 12,439 person-years, 157 of 1,090 in patients with diabe-
tes and 289 of 2,584 in patients without diabetes developed MACE, respectively [median follow-up duration 4.0 
(interquartile range 2.2 to 6.6) and 4.2 years (2.2 to 7.1) in diabetes and no diabetes groups, P = 0.180]. Patients 
with diabetes had higher incidence rates for MACE than patients without diabetes (30.9 vs. 23.2 per 1000 pop-
ulation per year, incidence rate ratio 1.32, 95% CI 1.08 to 1.62, P = 0.005). Among no diabetes S, no diabetes 
S + E, diabetes S, and diabetes S + E groups, the incidence rates of MACE were 24.9, 20.1, 35.3, and 22.8 per 1000 
population per year, respectively (Table 2). Patients those who received S + E had lower cumulative incidence 
of MACE than those who received S within the strata of diabetes and no diabetes (Fig. 2). In Cox proportional 
hazard model, unadjusted HR for MACE with the use of S + E (vs. S) were 0.56 (95% CI 0.39 to 0.82, P = 0.002) 
and 0.72 (95% CI 0.56 to 0.94, P = 0.015) in patients with or without diabetes, respectively. The association of 
ezetimibe-simvastatin combination therapy with MACE remained robust after adjustment for covariates in 
patients with diabetes (adjusted HR 0.52, 95% CI 0.39 to 0.75, P = 0.002) and in non-diabetic patients (adjusted 
HR 0.76, 95% CI 0.59 to 0.98, P = 0.047). Among individual components of MACE, ezetimibe-statin combination 
therapy was associated with a lower incidence rate of ACS (3.7 and 8.9 per 1000 person-years, incidence rate ratio 
0.41, P = 0.025) compared to simvastatin alone in patients with diabetes (Table 3), whereas lower incidence rate 
for CV mortality, coronary revascularization, and ischemic stroke by S + E did not reach statistical significance 
among diabetes and no diabetes groups. Patients with diabetes had higher incidence rate for all-cause mortality 
compared with those without diabetes (6.6 vs. 3.8 per 1000 person-years, incidence rate ratio 1.71, P = 0.013), 
whereas the incidence rate of mortality did not differ significantly between S + E and S groups within each stra-
tum of diabetes and no diabetes. Major reasons for all-cause death were as follows: multiorgan failure due to sep-
tic shock or pneumonia (N = 31, 34.0%), solid or hematologic cancer (N = 15, 16.4%), and uncontrolled bleeding 
(N = 13, 14.3%).
Interaction between diabetes and ezetimibe-simvastatin therapy. Relative to no diabetes S group, 
adjusted HR for diabetes S group was 1.23 (95% CI 0.97 to 1.58, P = 0.086), whereas S + E treatment was associated 
with a lower risk of MACE in both patients without diabetes (adjusted HR 0.76, 95% CI 0.59 to 0.98, P = 0.047) 
and patients with diabetes (adjusted HR 0.60, 95% CI 0.42 to 0.87, P = 0.007). Estimated RERI was −0.39 (95% 
CI −0.78 to −0.01, P = 0.044), which indicates a larger decrease of MACE risk by ezetimibe-simvastatin com-
bination than expected in patients with diabetes, indicating presence of significant negative interaction between 
diabetes and ezetimibe-simvastatin combination therapy. Interaction for MACE in multiplicative scale was also 
found to be significant between presence of diabetes and ezetimibe-simvastatin combination (HR 0.64, 95% CI 
0.41 to 0.98, P = 0.043).
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Discussion
In this propensity score-matched cohort study, we found that ezetimibe-simvastatin combination therapy was 
associated with a lower incidence rate of MACE compared with simvastatin monotherapy. The association of 
ezetimibe-simvastatin combination with lower risk of MACE was more enhanced in individuals with diabetes 
than in those without diabetes.
Our findings align with the results from a subsequent study based on the IMPROVE-IT data showing that 
the benefit of adding ezetimibe to statin was enhanced in patients with diabetes compared to patients without 
diabetes following recent ACS5. In this study, we found that the effect of ezetimibe-statin combination therapy on 
CV risk reduction was greater in patients with diabetes than in patients without diabetes and the study included 
Diabetes No diabetes
Diabetes vs. 
No diabetes
S + E (n = 545) S (n = 545) P
S + E 
(N = 1292) S (N = 1292) P P
Age (years) 70.3 ± 0.9 70.3 ± 0.9 0.997 67.7 ± 10.0 67.7 ± 10.9 0.985 <0.001
Men (%) 298 (54.7) 295 (54.1) 0.855 624 (48.3) 640 (49.5) 0.529 0.002
BMI (kg/m2) 25.1 ± 3.1 25.0 ± 3.4 0.776 24.4 ± 3.0 24.4 ± 3.1 0.681 <0.001
Current smoker 91 (16.7) 85 (15.6) 0.621 172 (13.3) 165 (12.8) 0.683 0.013
HTN 317 (58.2) 319 (58.5) 0.902 553 (42.8) 546 (42.3) 0.781 0.551
CKD 20 (3.7) 17 (3.10) 0.616 23 (1.8) 21 (1.6) 0.761 0.001
Previous UA 55 (10.1) 46 (8.4) 0.347 71 (5.5) 67 (5.2) 0.726 <0.001
Previous MI 29 (5.3) 27 (5.0) 0.784 40 (3.1) 37 (2.9) 0.729 0.001
Previous stroke 46 (8.4) 57 (10.5) 0.255 114 (8.8) 116 (9.0) 0.890 0.597
Aspirin 378 (69.4) 367 (67.3) 0.474 814 (63.0) 803 (62.2) 0.655 0.001
Clopidogrel 187 (34.3) 181 (33.2) 0.701 368 (28.5) 404 (31.3) 0.122 0.020
Beta blocker 267 (49.0) 254 (46.6) 0.431 482 (37.3) 491 (38.0) 0.715 <0.001
ACEi/ARB 311 (57.1) 295 (54.1) 0.329 551 (42.7) 539 (41.7) 0.633 <0.001
Insulin 100 (18.4) 92 (16.9) 0.525 0 (0.0) 0 (0.0) n/a n/a
Metformin 287 (52.7) 290 (53.2) 0.856 0 (0.0) 0 (0.0) n/a n/a
Sulfonylurea 234 (42.9) 226 (41.5) 0.624 0 (0.0) 0 (0.0) n/a n/a
Other DM med* 181 (33.2) 182 (33.4) 0.949 0 (0.0) 0 (0.0) n/a n/a
TC (mg/dl) 178 ± 48 179 ± 51 0.814 188 ± 50 188 ± 48 0.685 <0.001
LDL-C (mg/dl) 101 ± 40 101 ± 40 0.842 110 ± 43 111 ± 39 0.763 <0.001
HDL-C (mg/dl) 46 ± 13 46 ± 11 0.753 50 ± 12 50 ± 12 0.949 <0.001
Triglyceride (mg/dl) 163 ± 136 161 ± 109 0.773 141 ± 98 143 ± 82 0.573 <0.001
Fasting glucose (mg/dl) 130 ± 43 129 ± 39 0.716 100 ± 18 101 ± 22 0.399 <0.001
HbA1C (% [mmol/mol]) 7.3[56] ± 2.5 7.2[55] ± 1.3 0.364 n/a n/a n/a n/a
Creatinine (mg/dl) 1.03 ± 0.45 1.01 ± 0.36 0.496 0.94 ± 0.44 0.96 ± 0.47 0.188 <0.001
Table 1. Baseline characteristics of matched subjects according to the presence of diabetes. Notes: Data are 
presented as mean ± standard deviation or number (%) as appropriate. Abbreviations: ACEi/ARB, angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker; BMI, body mass index;; CKD, chronic kidney 
disease; DM, diabetes mellitus; HDL-C, high density lipoprotein cholesterol; HTN, hypertension; LDL-C, low 
density lipoprotein cholesterol; MI, myocardial infarction; S, simvastatin 20 mg alone; S + E, Combination of 
simvastatin 20 mg + ezetimibe 10 mg; TC, total cholesterol; UA, unstable angina. *Composite of dipeptidyl-
peptidase IV inhibitors, peroxisome proliferator-activated receptor gamma agonists, glucagon-like peptide-1 
agonists, and alpha-glucosidase inhibitors.
Events
Events per 1000 
person-year
Unadjusted HR 
(95% CI) P value
Adjusted HR 
(95% CI) P value
Diabetes
  S (n = 545) 116 35.3 Reference Reference
  S + E (n = 545) 41 22.8 0.56 (0.39–0.82) 0.002 0.52 (0.35–0.75) 0.001
No diabetes
  S (n = 1,292) 200 24.9 Reference Reference
  S + E (n = 1,292) 89 20.1 0.72 (0.56–0.94) 0.015 0.76 (0.59–0.98) 0.047
Table 2. Incidence of major adverse cardiovascular event for combination of ezetimibe 10 mg plus simvastatin 
20 mg compared to simvastatin 20 mg alone in subjects with or without diabetes. Notes: Covariates included in 
the adjusted model are as follows: age, sex, history of hypertension, ischemic stroke, revascularization, use of 
aspirin, clopidogrel, beta-blocker, serum glucose, and serum total cholesterol. Abbreviations: HR, hazard ratio; 
S, simvastatin 20 mg alone; S + E, combination of simvastatin 20 mg plus ezetimibe 10 mg.
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broader spectrum of patients with or without previous ASCVD in real-world setting. The incidence rate of MACE 
observed in this study was comparable to previously published reports4,11. Among individual components of 
MACE, the incidence rate of ACS was significantly lower in S + E than in S in subjects with diabetes. In con-
trast, the difference of CV mortality between treatment groups did not achieve statistical significance, which was 
consistent with results of previous clinical trials and meta-analysis4,12,13. However, these findings could also be 
attributed to limited statistical power to detect CV mortality as a separate clinical outcome due to the low num-
ber of events observed in this study. The association of ezetimibe-simvastatin combination therapy with a lower 
incidence rate of MACE can be supported by previously reports. In the PRECISE-IVUS Trial, ezetimibe add-on 
therapy yielded greater coronary plaque regression in patients with stable angina or an ACS compared to statin 
monotherapy14. Furthermore, lifelong genetic inhibition of NPC1L1 was found to be associated with reduced risk 
of coronary heart disease, suggesting an essential role of NPC1L1 on protection from CV disease15. These findings 
may portend the possibility of pleiotropic effects of ezetimibe on the atherosclerosis beyond the lipid-lowering 
effect. We found that the association between ezetimibe-simvastatin combination therapy and all-cause mortality 
did not reach statistical significance in this study. This might be attributed to relatively lower number of mortality 
cases than expected due to exclusion of subjects with any failure in kidney or liver function at baseline and the 
limited identification of mortality by issued death certificate at a single institution, although further studies are 
needed to confirm our findings.
Several biological mechanisms have been proposed for beneficial effects of ezetimibe–statin combination 
therapy in individuals with diabetes. Complementary decrease in LDL-C and non-HDL-C levels by ezetimibe 
combination therapy was significantly greater in patients with type 2 diabetes than those without diabetes16,17. 
NPC1L1 protein expression, a direct target of ezetimibe, was enhanced by hyperglycemia in cultured intestinal 
cells and mRNA expression of NPC1L1 was also increased in type 2 diabetes patients18,19. In addition to improve-
ment of lipid parameters, ezetimibe had favorable effects on fasting plasma glucose, insulin levels, and insulin 
resistance in patients with diabetes20. Of note, in a randomized placebo-controlled trial, 2 months of ezetimibe 
combination therapy did not change baseline glucose level but significantly improved insulin sensitivity, visceral 
fat area, and plasma adiponectin levels compared with statin monotherapy21. Diabetes and obesity are also known 
to activate the systemic inflammation22. In a pooled analysis of randomized, placebo-controlled trials of patients 
with hypercholesterolemia, the addition of ezetimibe to statin treatment significantly reduced C-reactive protein 
over statin monotherapy, although further studies are needed to validate this concept23.
Our study has several limitations. Despite the use of propensity score matching, possibilities of residual con-
founding due to study design and overestimation of treatment effect could not be excluded. Higher baseline CV 
risks of patients with diabetes might contribute to our results, although we found the presence of significant 
Figure 2. Kaplan-Meier curves for major adverse cardiovascular events (MACE) among simvastatin 20 mg 
alone and simvastatin 20 mg plus ezetimibe 10 mg groups stratified by the presence of diabetes. S indicates 
individuals treated with simvastatin 20 mg alone and S + E indicates individuals treated with simvastatin 20 mg 
plus ezetimibe 10 mg. The cumulative incidence of MACE in S (dash line) and S + E (solid line) group was 
compared (A) in individuals with diabetes and (B) those without diabetes.
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interaction between the presence of diabetes and ezetimibe-simvastatin combination therapy for the risk of 
MACE. Analyses on individual outcomes included in MACE in multivariate models were not possible due to 
insufficient number of cases for each outcome and limited statistical power. Since comparator statin was limited 
to simvastatin 20 mg for this study, we could not make any inference regarding combination of ezetimibe with 
other types of moderate to high intensity statins.
Conclusions
Ezetimibe-simvastatin combination therapy was associated with a lower incidence rate of MACE in individu-
als with or without diabetes, relative to simvastatin monotherapy. The beneficial effect of ezetimibe-simvastatin 
combination on the risk of MACE was more pronounced in individuals with diabetes compared to those without. 
Considering the worldwide epidemic of diabetes, combination therapy of ezetimibe and statin might provide an 
effective strategy to combat residual CV risks in diabetes, which merit further investigation.
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Event number (Incidence 
rate, per 1,000 person-years) S + E S IRR (95% CI) P-value
All-cause mortality
  Diabetes 12 (6.3) 26 (6.7) 0.93 (0.42–1.92) 0.865
  No diabetes 21 (4.4) 32 (3.5) 1.26 (0.69–2.27) 0.396
MACE
  Diabetes 41 (22.8) 116 (35.3) 0.64 (0.44–0.92) 0.013
  No diabetes 89 (20.1) 200 (24.9) 0.80 (0.62–1.03) 0.087
CV mortality
  Diabetes 0 (0.0) 1 (0.3) 0.00 (0.00–79.04) 0.669
  No diabetes 0 (0.0) 1 (0.1) 0.00 (0.00–75.45) 0.659
ACS
  Diabetes 7 (3.7) 33 (8.9) 0.41 (0.15–0.95) 0.025
  No diabetes 17 (3.6) 50 (5.7) 0.64 (0.34–1.13) 0.107
Coronary revascularization
  Diabetes 26 (14.2) 62 (17.5) 0.81 (0.49–1.30) 0.374
  No diabetes 60 (13.3) 124 (14.7) 0.90 (0.65–1.24) 0.544
Ischemic stroke
  Diabetes 8 (4.2) 20 (5.3) 0.79 (0.30–1.88) 0.602
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